Tae Hata
Otowa, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 20 publications
Cancer Cachexia Predicts Benefit of Immunotherapy Plus Chemotherapy in EGFR-mutant NSCLC After TKI Resistance.
Journal: Anticancer research
Published: February 28, 2026
Prevalence and molecular landscape of NRG1 fusions in Japanese solid tumors: a nationwide data analysis using the C-CAT database.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: November 05, 2025
Initial biomarker testing strategies and clinical outcomes in advanced non-small cell lung cancer.
Journal: iScience
Published: October 02, 2025
Efficacy and Safety of Chemoimmunotherapy in Patients With Advanced Non-small Cell Lung Cancer With Pre-existing Interstitial Pneumonia and Low PD-L1 Expression.
Journal: Anticancer research
Published: July 08, 2025
Real-world treatment outcomes before and after chemoimmunotherapy approval in EGFR-mutant NSCLC after EGFR-TKI failure: a Japanese cohort study.
Journal: International journal of clinical oncology
Published: May 05, 2025
Analysis of Poor Prognostic Factors and Treatment Strategies in Platinum-Based Systemic Therapy After EGFR-TKI Failure in Patients With Advanced Nonsmall Cell Lung Cancer Harboring EGFR Mutations.
Journal: Clinical lung cancer
Published: April 30, 2025
Impact of EGFR Mutation Subtypes on Response to Chemoimmunotherapy and Chemotherapy in Non-Small-Cell Lung Cancer After EGFR-TKI Failure.
Journal: Targeted oncology
Published: April 08, 2025
Chemoimmunotherapy Outcomes and Prognostic Factors in Patients with Advanced, Low PD-L1-Expressing Non-Small Cell Lung Cancer.
Journal: Cancer research communications
Published: March 19, 2025
Outcomes of chemotherapy with or without immunotherapy in older patients with non-small cell lung cancer and low PD-L1 expression.
Journal: Translational lung cancer research
Published: December 25, 2024
Impact of immune-related adverse events on clinical outcomes in patients with advanced non-small cell lung cancer with low PD-L1 expression, focusing on pneumonitis: a multicenter retrospective study in Japan.
Journal: Translational lung cancer research
Published: December 04, 2024
Exploration of clinical Biomarkers for guiding treatment selection between chemotherapy and combination therapy with Atezolizumab, Bevacizumab, Carboplatin, and Paclitaxel in EGFR-Mutant NSCLC patients after EGFR-TKI Therapy: The SPIRAL-STEP study.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: November 21, 2024
Comparative analysis of first-line treatment in NSCLC including unresectable stage III (IIIB/IIIC) and stage IV with low PD-L1 expression: Clinical trial eligible versus ineligible patients.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: October 06, 2024
Last Updated: 09/26/2026